Zhejiang Garden Biopharmaceutical Co.,Ltd. (SHE:300401)
China flag China · Delayed Price · Currency is CNY
13.37
-0.36 (-2.62%)
May 20, 2026, 1:25 PM CST

SHE:300401 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,1701,2201,2211,0821,3971,107
Other Revenue
17.717.722.4512.9320.399.75
1,1881,2371,2431,0951,4181,117
Revenue Growth (YoY)
-4.16%-0.47%13.58%-22.78%26.89%69.40%
Cost of Revenue
556.46555.88519.59441.4486.37350.66
Gross Profit
631.43681.52723.7653.25931.14766.44
Selling, General & Admin
220.69234.8308.87378.77444.55257.61
Research & Development
72.4365.4683.7890.9170.3459.28
Other Operating Expenses
21.9618.5113.2416.4416.243.48
Operating Expenses
313.1320.89407.84483.74533.66320.69
Operating Income
318.33360.63315.86169.51397.48445.75
Interest Expense
-31.91-32.47-35.63-38.41-21.82-10.81
Interest & Investment Income
10.519.6411.0120.5413.7532.49
Currency Exchange Gain (Loss)
-1.92-1.926.317.0211.1-2.79
Other Non Operating Income (Expenses)
-16.38-0.69-0.35-0.3-0.65-0.19
EBT Excluding Unusual Items
278.63335.19297.19158.36399.86464.46
Gain (Loss) on Sale of Investments
3.233.770.25-0.34-2.830.4
Gain (Loss) on Sale of Assets
-2.24-2.2431.53-0.0417.876.22
Asset Writedown
-3.97-3.98-0.44-0.22-1.01-0.09
Other Unusual Items
22.0119.7630.1753.2728.6748.38
Pretax Income
297.67352.5358.69211.04442.48589.37
Income Tax Expense
39.0547.6449.4818.758.7675.42
Earnings From Continuing Operations
258.62304.86309.21192.35383.72513.94
Minority Interest in Earnings
0.010.010---30.18
Net Income
258.62304.86309.21192.35383.72483.77
Net Income to Common
258.62304.86309.21192.35383.72483.77
Net Income Growth
-17.70%-1.41%60.76%-49.87%-20.68%83.79%
Shares Outstanding (Basic)
550544542550548544
Shares Outstanding (Diluted)
603598595601548544
Shares Change (YoY)
4.71%0.53%-1.07%9.65%0.85%7.38%
EPS (Basic)
0.470.560.570.350.700.89
EPS (Diluted)
0.430.510.520.320.700.89
EPS Growth
-21.40%-1.92%62.50%-54.29%-21.35%71.15%
Free Cash Flow
197.07112.78-13.97-84.57-2.89-203.33
Free Cash Flow Per Share
0.330.19-0.02-0.14-0.01-0.37
Dividend Per Share
0.1130.1130.1140.0710.1400.188
Dividend Growth
-0.88%-0.88%60.56%-49.29%-25.53%82.52%
Gross Margin
53.16%55.08%58.21%59.68%65.69%68.61%
Operating Margin
26.80%29.14%25.41%15.48%28.04%39.90%
Profit Margin
21.77%24.64%24.87%17.57%27.07%43.31%
Free Cash Flow Margin
16.59%9.11%-1.12%-7.72%-0.20%-18.20%
EBITDA
502.01538.72471.63302.82458.27490.2
EBITDA Margin
42.26%43.54%37.93%27.66%32.33%43.88%
D&A For EBITDA
183.67178.09155.77133.3160.7944.45
EBIT
318.33360.63315.86169.51397.48445.75
EBIT Margin
26.80%29.14%25.41%15.48%28.04%39.90%
Effective Tax Rate
13.12%13.52%13.80%8.86%13.28%12.80%
Revenue as Reported
1,1881,2371,2431,0951,4181,117
Advertising Expenses
-3.112.370.970.70.8
Source: S&P Global Market Intelligence. Standard template. Financial Sources.